Objectives: To quantify the epidemiology of bladder cancer in Africa to guide a targeted public health response and support research initiatives. Methods: We systematically searched publicly available sources for population-based registry studies reporting the incidence of bladder cancer in Africa between January 1980 and June 2017. Crude incidence rates of bladder cancer were extracted. A Bayesian network meta-analysis model was used to estimate incidence rates. Results: The search returned 1328 studies. A total of 22 studies carried out across 15 African countries met our pre-defined selection criteria. Heterogeneity across studies was high (I 2 = 98.9%, P < 0.001). The pooled incidence of bladder cancer in Africa was 7.0 (95% credible interval 5.8-8.3) per 100 000 population in men and 1.8 (95% credible interval 1.2-2.6) per 100 000 in women. The incidence of bladder cancer was consistently higher in North Africa in both sexes. Among men, we estimated a pooled incidence of 10.1 (95% credible interval 7.9-11.9) per 100 000 in North Africa and 5.0 (95% credible interval 3.8-6.6) per 100 000 in sub-Saharan Africa. In women, the pooled incidence was 2.0 (95% credible interval 1.0-3.0) per 100 000 and 1.5 (95% credible interval 0.9-2.0) per 100 000 in North Africa and sub-Saharan Africa, respectively. Incidence rates increased significantly among men from 5.6 (95% credible interval 4.2-7.2) in the 1990s to 8.5 (95% credible interval 6.9-10.1) per 100 000 in 2010. Conclusions: The present study suggests a growing incidence of bladder cancer in Africa in recent years, particularly among men and in North Africa. This study also highlights the lack of quality data sources and collection of essential clinical and epidemiological data in several African countries, and this hinders public health planning.
Introduction
Bladder cancer is the ninth most common cancer worldwide, with an estimated 430 000 new cases and 165 000 deaths in 2012. 1 Among the leading cancer sites in Africa, there were an estimated 24 437 new cases and 13 268 deaths from bladder cancer in 2012. 1 The risks of bladder cancer appear to vary across world regions, correlating with smoking and occupational exposures to carcinogens in developed countries, and with chronic bladder urothelial irritation from Schistosoma haematobium infection in Africa and the Middle East. 2 However, this is changing as several African countries undergo social and economic development and changes. That is, while the histological subtype of bladder cancer in most parts of Africa has historically been SCC (linked to schistosomiasis), a gradual shift to TCC linked to increased cigarette smoking and other lifestyle changes associated with urbanization and industrialization has been documented. 3, 4 Although the general awareness of cancer in Africa continues to increase, 5 health systems are generally fractured and underfinanced, and thus cancer screening services supporting early cancer diagnosis and prompt treatment are largely unavailable. For those diagnosed with cancer, a lack of subspecialty training in oncology and essential cancer medicines results in suboptimal management plans and care. 6 Ongoing inadequate sanitation and hygiene also promote the recurrence of urinary schistosomiasis in many parts of Africa.
In the presence of suboptimal epidemiological data and limited histological data, the present study sought to systematically review and coalesce available data on the incidence of bladder cancer in Africa to provide a comprehensive epidemiological report that can guide relevant research and public health policy in the region.
Methods

Search strategy and data sources
We systematically searched MEDLINE, EMBASE, Global Health, AJOL Online, the IACR website, the World Health Organization AFRO site, GLOBOCAN studies, [7] [8] [9] CI5 series, 10 Cancer in Africa: Epidemiology and Prevention, 5 and Google Scholar for population-based registry studies between January 1980 through June 2017 reporting the incidence of bladder cancer in Africa (Table 1) . Reference lists of studies were hand-searched to ensure completeness in the data capture.
This study did not involve any human participants or animals. All data are from published works or summaries of completed data collections. This review was conducted in strict compliance with the PRISMA guidelines (Appendix S1).
Selection criteria
Without language restriction, we included population-based registry studies, as defined by IACR (registries that collect data from different sources in the population on all new cancer cases in well-defined populations), carried out in Africa that reported crude estimates of the incidence of bladder cancer. 10 For inclusion, a study had to have utilized histologically-confirmed bladder cancer. We excluded hospital-based reports, studies on non-human subjects, reviews, case reports, opinions or editorials.
Data extraction
Data extraction was carried out by two independent reviewers (AA and RAD) who separately screened studies against the selection criteria (j = 92%). Disagreements were resolved by a third reviewer (DA). Data and other relevant information, including location, period, design, cancer registry, histological confirmation of diagnosis, data collation methods, coding criteria, data ascertainment and modality with which population or person-years at risk were generated, and the mean age (or age range), cancer cases and crude incidence were extracted from each study.
Quality criteria
Studies were assessed for five quality measures:
1 The cancer registration process, which grades how the cancer registries collated and ascertained their data.
2 The coding criteria used across studies were also reviewed to determine if the cancer types were reported according to the primary anatomical site (topography) or cellular characteristics (morphology-histology, behavior and grade) using the ICD and ICD-O guidelines. [11] [12] [13] 3 How the population or person-years at risk was generated in each study. 4 Whether the population covered in each study was representative of the target (subnational), and 5 National populations.
Each criterion was scored one (1), with studies graded as high (4) (5) , moderate (2-3) or low (0-1) quality (Table S1 ). The quality assessment was used in another study. 14 
Statistical analysis
A Bayesian network meta-analysis model was used to estimate the pooled incidence rates of bladder cancer per 100 000 population from the raw data. 15, 16 This model was selected due to the lack of data across calendar years, age groups, AFROs and countries. This modeling approach created hierarchical models and included several covariates without leading to biases due to overfitting the data. This is possible, as the model is based on a combination of information obtained from the bladder cancer data extracted (the likelihood) with a previous known or subjective knowledge (the prior) to generate an update on the process under investigation (the posterior probability). In this approach, we used an extension of the random effects model on the Bayesian meta-analysis models using uninformative priors (i.e. the prior was subjective, as this was based on a balance of available data). 17 From the Bayesian model, we extracted a posterior of plausible estimates, as contained within the posterior interval 0.05-0.95, and averaged them to generate the posterior mean estimate. The posterior mean estimates corresponded to the pooled incidence rates of bladder cancer, and were obtained by averaging over each strata of the posterior distribution of the expectation of likelihood function, respectively, for all Africa (sorted by sex), AFROs, countries, study period and mean age of the patients. By doing this, we eliminated all non-plausible values from the tails of the distribution, and averaged only those within the values of the CI. To verify that the fit of the Bayesian model appropriately summarized cancer explanatory variables as contained in our dataset, we carried out a posterior predictive check using: (i) graphical inspection of the posterior distribution of the model or nodes effects; (ii) graphical inspection of the observed data and the one generated by the model (marginal distribution of the response variable); (iii) Bayesian tests to verify if the moments of the observed data matched those generated by the model; and (iv) the WAIC2, 18 which is a numerical metric used to measure the predictive accuracy of a fitted Bayesian model, with a lower WAIC2 score indicating better prediction or model fit. 18 All statistical analyses were carried out using the package rstan probabilistic programming language (Num-FOCUS, Austin, TX, USA) in the R programming language (The R Foundation for Statistical Computing, Vienna, Austria). 19 See Appendix S2 for details.
Results
Search results
The literature search returned a total of 1328 publications. Out of these, 1321 publications were from four databases: PubMed (n = 537), EMBASE (n = 612), Global Health (n = 164) and AJOL (n = 8). After all of the studies had been collated and duplicates removed, 812 records remained. Based on article screening, a further 726 studies were excluded, leaving a total of 86 full-text manuscripts to be assessed. After applying the selection criteria, 64 studies were excluded (46 articles did not specify study designs and/or clarify their cancer registration process, and 18 studies did not define catchment population). A total of 22 studies were retained for the present study ( Fig. 1 ; Appendix S3). 
Study characteristics
The retained 22 studies were carried out across 15 African countries, with eight studies retrieved from North Africa, one from Central Africa, four from East Africa, four from Southern Africa and five from West Africa ( Table 2 ). The study period across all studies ranged from 1986 to 2010. The mean age across studies ranged from 36.8 to 61 years, with participants mostly in the 50-59 years age group (60%), followed by the 40-49 years age group (30%). A total of 15 studies (68%) were graded as high quality (Table S1 ).
Bayesian network modeling
Significant associations were observed between the incidence of bladder cancer and increasing age, sex and African subregion (P > F = 0.0003, adjusted R 2 = 39.7%). All the Bayesian networks models showed agreement with the scale of the observed datasets ( Figs 2,3) ; however, we used model 6, as this has the best model fit (i.e. lowest WAIC2 score), to generate pooled estimates of bladder cancer incidence (Table 3 ; Fig. S1 ).
Pooled incidence rate of bladder cancer in Africa
Continent-wide Across AFROs, variations were observed in the reported incidence of bladder cancer, with high heterogeneity estimated across studies (I 2 = 98.9%, P < 0.001). The pooled crude incidence of bladder cancer in Africa was significantly higher among men compared with women, with incidence estimated at 7.0 (95% CI 5.8-8.3) per 100 000 population per year in men, and 1.8 (95% CI 1.2-2.6) per 100 000 in women (Table 4) .
Regions
The incidence of bladder cancer was consistently higher in North Africa in both sexes. Among men, we estimated a pooled incidence of 10.1 (95% CI 7.9-11.9) per 100 000 in North Africa and 5.0 (95% CI 3.8-6.6) per 100 000 in SSA. In women, the pooled incidence was 2.0 (95% CI 1.0-3.0) per 100 000 and 1.5 (95% CI 0.9-2.0) per 100 000 in North Africa and SSA, respectively. Among men in SSA, Southern Africa had a relatively higher incidence at 7.1 (95% CI 4.7-9.7) per 100 000, followed by West Africa at 4.5 (95% CI 2.9-7.3) per 100 000, whereas the incidence in Central and East Africa were 3.8 (95% CI 0.9-9.4) and 3.5 (95% CI 2.7-5.4) per 100 000, respectively. Among women, the incidence across SSA subregions were comparable, with Central, East, Southern and West Africa having 1.3 (95% CI 0.4-2.5), 1.7 (95% CI 1.1-2.5), 1.5 (95% CI 0.8-2.6) and 2.0 (95% CI 1.3-2.9) per 100 000, respectively (Table 4; Figs 4,5).
Time trends and age groups
Among men, the incidence of bladder cancer increased from 5.6 (95% CI 4.2-7.2) in the 1990s to 8.5 (95% CI 6.9-10.1) per 100 000 in 2010. Among women, a minimal decrease in incidence was observed over the same period. Meanwhile, an increase in bladder cancer incidence was also observed with advancing age among men, with the incidence increasing from 4.8 (95% CI 1.9-11.9) per 100 000 among persons aged 30-39 years to 13.3 (95% CI 9.7-15.5) per 100 000 among persons aged ≥60 years. The incidence rates were, however, comparable between these age groups among women (Table 4) . 
Discussion
The present study assembled a range of diverse datasets, mainly population-based cancer registries, to provide continent-wide and subregional estimates of bladder cancer incidence in Africa. Our findings show a significantly higher incidence of bladder cancer among men (7.0 per 100 000) compared with women (1.8 per 100 000). This approximately 4:1 disparity in disease incidence has been observed in other settings and cohort studies. 1 In addition, our estimates, which use a different statistical method, are comparable with the 2012 GLOBOCAN estimates, where the male and female bladder cancer incidence was 6.3 and 2.1 per 100 000 population, respectively (Table 4) . 8 This sex difference is presumably driven to some extent by differences in cigarette smoking, although the rates of cigarette smoking are rapidly increasing among both sexes across Africa, [20] [21] [22] and there does not appear to be a sex-specific difference in the likelihood of S. haematobium infection. 4, 23 Dobruch et al. reported that several biological and epidemiological factors underlie sex differences in bladder cancer incidence, although women, despite a relatively lower incidence rate, particularly present with advanced tumors at diagnosis and higher mortality rates owing to delays in urological evaluations. 24 Meanwhile, we observed an increase in the incidence of bladder cancer among men from 5.6 to 8.5 per 100 000 between 1990 and 2010.
We noted a consistently higher bladder cancer incidence in North Africa in both sexes. Our estimates again are similar to those reported by GLOBOCAN 8 and the GBD collaborators. 25 For example, in 2012, GLOBOCAN estimated a bladder cancer incidence at 15.1 and 3.0 per 100 000 among men, and 3.2 and 1.6 per 100 000 among women, for North Africa and SSA, respectively; 8 and the GBD collaborators also estimated an overall incidence of bladder cancer at 8.3 and 5.3 per 100 000, respectively, for the two regions (Table 4) . 25 Indeed, bladder cancer incidence rates in SSA have been reported as among the lowest in the world, but the North African estimates are actually comparable with incidence rates obtained in Europe (18.0 per 100 000), the Middle East (17.2 per 100 000) and the Americas (12.9 per 100 000). 1, 8 Bladder cancer is regarded as the most common malignancy in Egypt, constituting >30% of cancers. 26 The higher rates in Egypt and North Africa have generally been linked to the proximity with the Nile delta region, where S. haematobium infection is widespread, and increased cigarette smoking. 23 In contrast to other world regions, South-East Asia and Western Pacific regions reportedly have lower bladder cancer incidence at 2.0 and 3.5 per 100 000, respectively. 8 The strength of the present study is a breakdown of cancer incidence across SSA regions, study periods and age groups, which to the best of our knowledge, is the first study on bladder cancer incidence offering such detail. We found that the Southern Africa region had a relatively higher bladder cancer incidence at 7.1 per 100 000, compared with other SSA regions. Although there are no clearly comparable estimates, Antoni et al. noted that women from Malawi had the second highest incidence rate of bladder cancer in their study, at 9.2 per 100 000. 1 The reasons for these regional differences in SSA are not clear; however, the presence of several riverine communities favoring breeding of Schistosoma species appear to be a key factor. 23 Owing to its association with schistosomiasis and the inability of African countries to effectively halt the breeding and transmission of Schistosoma species, bladder cancer has been called a "neglected tropical disease." 23, 27 Although the World Health Organization supported the SCI introduced across African states in 2002, the program has been ineffective in many SSA regions due to incomplete drug distribution resulting in insufficient population coverage, particularly of infants and preschool aged children who suffer disproportionately from Schistosoma infection. 27 Primary prevention might be the cheapest and most effective public health response to bladder cancer in Africa, particularly by intensifying eradication programs for schistosomiasis through widespread praziquantel therapy, the provision of potable water and appropriate sanitation measures.
Suboptimal control of primary exposures for bladder disease is further confounded by an absence of widespread population-based cancer screening programs. This contributes to a late presentation of cases, usually marked with a low probability of curative treatment. 4 Many urology centers still lack basic cystoscopy equipment, and there are limited skilled personnel and training facilities to support "basic" surgeries, such as TURBT. 1, 2 Despite attempts to provide a representative and comprehensive report on the incidence of bladder cancer in Africa, the lack of data from many countries remains a major limitation of the present study. Furthermore, many studies were carried out in subnational population-based cancer registries, mainly covering provinces, districts or major cities within a country. This is even marked in Central Africa, with only one study selected from this region. These geographic and demographic differences are reflected in our estimate of heterogeneity (I 2 > 98%, P < 0.001). Further, variations in study designs, cancer registration, coding and abstracting, and the estimation of cancer incidence are important sources of heterogeneity that hinder several active disease assessment efforts. Another important source of heterogeneity might be due to the differences in tumor subtypes (SCC/TCC), which we could not ascertain from the available data. Furthermore, we could not specifically describe the smoking prevalence and rates of schistosomiasis infection across population groups, and how these relate to variations in bladder cancer incidence in African subregions. Another limitation of this study is the inability to estimate age-standardized rates of bladder cancer incidence on the continent. This is mainly due to the lack of data on age from many studies. We could also have missed some important findings by excluding hospital- based studies; however, considering that several hospitalbased reports do not clearly define the population covered or person-years at risk, we believe including these studies might affect the overall representativeness of our estimates. These limitations aside, the present findings offer the closest possible representation of the incidence of bladder cancer in Africa considering the available data. To augment the contribution of our work, we have provided all our data to support future efforts by others. It is our hope that these findings might encourage policy redirection and resource allocation towards improved primary prevention, early diagnosis, improved research, and capacity building targeted at bladder cancer on the continent.
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